SecBot SecBot
8-K ·Filed Aug 11, 2026

TNGX

Tango Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-343434
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The 92% ORR and 90% 6-month PFS data for vopimetostat + daraxonrasib in pancreatic cancer is a transformative catalyst that validates the combination approach and supports a rapid path to Phase 3. The $1.0B cash runway removes near-term financing risk through key data readouts. Traders should watch for the ESMO presentation in October and any regulatory updates on the registrational path, which could drive further upside. The widening net loss is expected for a clinical-stage biotech scaling up for late-stage development and commercialization.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ERAS-0015

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1
Time to market
~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
Next catalyst
None dated

What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

Price Chart

Loading chart...

Executive Summary

Tango Therapeutics reported Q2 2026 financial results, highlighting a net loss of $55.3M ($0.37/share) vs $38.9M ($0.35/share) in Q2 2025, with no collaboration revenue. The key catalyst is the positive Phase 1/2 data for vopimetostat + daraxonrasib in pancreatic cancer (92% ORR, 90% 6-month PFS), which the company is advancing toward a registrational path and Phase 3 trial. The cash position surged to $1.0B from $380M in Q1 2026, extending runway into 2028, while the company appointed a Chief Commercialization Officer and a new Board Chairman, signaling late-stage preparation.

Key Financial Metrics

EPS
−$0.37
Revenue
$0.00
Rating
in line

Key Facts

  • Net loss of $55.3M ($0.37/share) for Q2 2026 vs $38.9M ($0.35/share) in Q2 2025
  • Cash, cash equivalents and marketable securities of $1.0 billion as of June 30, 2026, up from $379.8M at March 31, 2026
  • Phase 1/2 data showed vopimetostat + daraxonrasib achieved 92% objective response rate and 90% six-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer
  • Company is working with regulators and Revolution Medicines toward a registrational plan for vopimetostat plus daraxonrasib
  • Fatma Ocak appointed Chief Commercialization Officer; Robert Azelby appointed Chairman of the Board
  • Phase 1/2 data to be presented at 2026 ESMO Congress (Oct 23-27)
  • R&D expenses increased to $37.2M from $32.8M YoY; G&A expenses doubled to $22.6M from $11.3M YoY

Financial Impact

Net loss widened by $16.4M YoY to $55.3M; cash position increased by $620M sequentially to $1.0B

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Clinical trial risks in Phase 3 development
  • Regulatory uncertainty around registrational path
  • Execution risk in transitioning to late-stage and commercial organization
  • Dependence on collaboration with Revolution Medicines
  • Potential dilution from future capital raises despite current cash position

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-343434
Document: tngx-20260811.htm0001193125-26-343434
Document: 0001193125-26-343434-index-headers.html0001193125-26-343434
Document: 0001193125-26-343434-index.html0001193125-26-343434
Document: 0001193125-26-343434.txt0001193125-26-343434
8-K Data (Synthetic)0001193125-26-343434

Track record

27 reports on TNGX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 Viewing No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026